Market maturation of a blood plasma separation module enabling plasma based diagnostic point-of-care devices

Informations projet

ACOUPLASMA

N° de convention de subvention: 836542

DOI

10.3030/836542

Projet clôturé

Date de signature de la CE 26 Novembre 2018

Date de début 1 Octobre 2018

Date de fin 28 Février 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

ACOUSORT AB
Sweden

Periodic Reporting for period 1 - ACOUPLASMA (Market maturation of a blood plasma separation module enabling plasma based diagnostic point-of-care devices)

Période du rapport: 2018-10-01 au 2019-02-28

Résumé du contexte et des objectifs généraux du projet

Given the rapid ageing of the population and rise in chronic diseases, it is now more critical than ever to develop new solutions that positively impact the global healthcare system and the population wellbeing.
AcouSort has developed a technological platform based on acoustic forces to separate, enrich and wash cells and other particles This technique can perform almost any operation that is normally done by centrifugation in the biology or clinical lab. With an automated flow we can handle small samples and low cell concentrations. We are currently selling two R&D benchtop devices based on this technology, named AcouTrap and AcouWash.
In our pipeline is AcouPlasma the first example of the company’s long-term strategy to provide components and modules for life science analytical/diagnostic devices. The AcouPlasma solution offers high quality separation of blood plasma from cells in whole blood in a module, eliminating the need of time consuming and laborious centrifugation. Through a unique design, it facilitates cost-effective automation and in-line integration with the sample workflow required to take plasma-based laboratory tests to point-of-care.
It is now time to mature our solution towards a commercial device to be integrated into cartridges for Lab-on-Chip test devices for the in vitro diagnostic market. The Phase 1 project was aimed at developing an in-depth business plan.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

In line with the main objective of the SME instrument Phase 1 project, we have during the action:
1) Started to map and engage with key stakeholders, including suppliers and customers
2) Developed an in-depth market study compiling it into a business plan
3) Performed a Freedom to operate analysis
4) Prepared the Phase 2 project.
Most importantly, we have during the project confirmed that our solution clearly addresses the issues described above, matching customers and end-users’ needs.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

There is currently a lack of cost-effective Lab-on-a-chip solutions for blood plasma separation for integration into plasma-based diagnostic devices, which is limiting the point-of-care market expansion. AcouPlasma´s performance has potential to increase patient safety and hospitals/laboratories efficiency, finances and reputation.

acouplasma.jpg